Skip to main content

Table 2 Comparison of therapeutic and angiographic characteristics of study participants

From: ACEF performed better than other risk scores in non-ST-elevation acute coronary syndrome during long term follow-up

Variables MACE Total (n = 276) p value
No (n = 212) Yes (n = 64)
Treatments     0.071
 Conservative 43 (20.3) 20 (31.3) 63 (22.8)  
 PCI 83 (39.2) 27 (42.2) 110 (39.9)  
 CABG 86 (40.6) 17 (26.6) 103 (37.3)  
Coronary angiogram
 Left main disease 27 (12.7) 5 (7.8) 32 (11.6) 0.281
 Single-vessel disease 82 (38.7) 23 (35.9) 105 (38.0) 0.692
 Two-vessel disease 39 (18.4) 17 (26.6) 56 (20.3) 0.155
 Three-vessel disease 79 (37.3) 20 (31.3) 99 (35.9) 0.177
Discharge therapy     
 Beta blockers 158 (74.5) 42 (65.6) 200 (72.5) 0.162
 ACE-I/ARB 132 (62.) 44 (68.8) 176 (63.8) 0.344
 ASA 199 (93.9) 60 (93.8) 259 (93.8) 0.973
 P2Y12 inhibitors 182 (85.8) 50 (78.1) 232 (84.1) 0.139
 Statins 196 (92.5) 56 (87.5) 252 (91.3) 0.218
Risk scores     
 GRACE 2.0 99.0 (80.3–116.0) 107.5 (88.5–127.3) 100.0 (82.0–120.0) 0.072*
 ACEF 1.1 (0.9–1.3) 1.3 (0.9–1.4) 1.2 (0.9–1.3) 0.002
 SYNTAX 14.0 (8.0–23.4) 13.3 (7.0–26.0) 14.0 (8.0–24.0) 0.869
 Clinical SYNTAX 14.8 (8.6–26.9) 15.1 (8.4–31.0) 14.9 (8.6–27.7) 0.462
 SYNTAX II PCI 25.5 (20.4–33.7) 29.8 (24.1–38.5) 26.8 (20.8–34.8) 0.001*
 SYNTAX II CABG 24.9 (17.2–32.0) 27.0 (18.7–36.4) 25.5 (18.1–33.6) 0.038*
  1. Data are expressed as number (percent) or median (interquartile range)
  2. ACE-I—angiotensin converting enzyme inhibitors; ACEF—Age, Creatinine and Ejection Fraction risk score; ARB—angiotensin receptor blockers; ASA—acetylsalicylic acid; CABG—coronary artery bypass grafting; GRACE—Global Registry of Acute coronary events risk score; MACE—major adverse cardiovascular events; PCI—percutaneous coronary intervention; SYNTAX—The Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery risk score
  3. *Student’s T test; Chi-square test; Mann–Whitney U test